A Rich, Diversified Portfolio

contentheader_ourportfolio.jpg

Sandoz, a market leader in generics, holds one of the most significant product portfolio in Canada with over 225 molecules, including 22 of the 25 most prescribed generic products in the country. Each year, Sandoz Canada expands and diversifies its high-quality, affordable medicines thanks to in-house development of new products and the acquisition of right off-patent drugs.

Sandoz Canada is also a worldwide centre of excellence for injectable products within the Sandoz Group.

Sandoz distinguishes itself through its ability to develop and manufacture generics that are differentiated. Its broad portfolio ranges from advanced application forms, such as oral solids, through complex technologies, such as inhalants and injectables, and includes transdermal patches, implants and new subsequent entry biologics.

 

Related content

Biosimilars or Follow-On Biologics

teaser_biosimilars.jpg

Sandoz is the pioneer and undisputed global leader in the rapidly emerging market for biosimilars, also known as follow-on biologics (or biopharmaceuticals).

FAQs

teaser_faq.jpg

 

Want to know more about our products?